Insmed

Insmed to evaluate potential initiation of phase II trial for IPLEX
in MMD patients with severe insulin resistance


posted on June 25, 2009 - 7:08am
RICHMOND, VA., June 25, 2009 - Insmed Inc. (NASDAQ CM: INSM), a biopharmaceutical company, today announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX™ (mecasermin rinfabate) in patients with myotonic muscular dystrophy (“MMD”).  The randomized, double-blind, placebo-controlled Phase II trial conducted in 13 centers across the U.S.
posted on May 1, 2008 - 10:21am
QUEST Vol. 15, No. 3
This article includes items about: Duchenne muscular dystrophy, limb-girdle muscular dystrophy, Becker muscular dystrophy, myotonic muscular dystrophy, fascioscapulohumeral muscular dystrophy, Charcot-Marie-Tooth disease, spinal muscular atrophy, Friedreich's ataxia, myasthenia gravis and centronuclear myopathy
posted on September 1, 2007 - 11:06am
QUEST Vol. 14, No. 5
Featured in this issue: News about clinical trials in Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, Pompe disease and myotonic muscular dystrophy type 1